Jucara and açai fruit-based dietary supplements
The present invention relates to stable, palatable, freeze-dried, fruit-based dietary supplements. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit and Jucara fruit.
1. A method of inhibiting cyclooxygenase enzyme activity in a mammal, the method comprising administering to the mammal an effective amount of a dietary supplement comprising freeze-dried Açai fruit pulp composition, wherein the composition comprises:
(a) a total anthocyanin concentration greater than about 1 milligram per gram total weight;
(b) an ORAC FL value greater than about 350 micromole TE per gram total weight; and
(c) a residual water content less than about 3 weight percent of the total weight; or
an effective amount of a freeze-dried Açai fruit pulp composition, wherein the composition comprises a cyclooxygenase inhibition value greater than about 15 Aspirin® mg equivalent per gram total weight and a residual water content less than about 3 weight percent of the total weight.
2. The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable carrier.
3. The method of claim 1 , wherein the composition is administered by a route of administration selected from the group consisting of: oral, intravenous, intraperitoneal, subcutaneous, intramuscular, intraarticular, intraarterial, intracerebral, intracerebellar, intrabronchial, intrathecal, topical, and aerosol route.
4. A method of treating a disease or an injury associated with increased cyclooxygenase enzyme activity in a mammal, the method comprising administering to the mammal an effective amount of a dietary supplement comprising a freeze-dried Açai fruit pulp composition, wherein the composition comprises:
(a) a total anthocyanin concentration greater than about 1 milligram per gram total weight;
(b) an ORAC FL value greater than about 350 micromole TE per gram total weight; and
(c) a residual water content less than about 3 weight percent of the total weight; or
an effective amount of a freeze-dried Açai fruit pulp composition, wherein the composition comprises a cyclooxygenase inhibition value greater than about 15 Aspirin® mg equivalent per gram total weight and a residual water content less than about 3 weight percent of the total weight.
5. The method of claim 4 , wherein the composition further comprises a pharmaceutically acceptable carrier.
6. The method of claim 4 , wherein the composition is administered by a route of administration selected from the group consisting of: oral, intravenous, intraperitoneal, subcutaneous, intramuscular, intraarticular, intraarterial, intracerebral, intracerebellar, intrabronchial, intrathecal, topical, and aerosol route.
7. The method of claim 4 , wherein the disease or injury is selected from the group consisting of: cancer, colon cancer, breast cancer, inflammatory bowel disease, Crohn's disease, vascular disease, arthritis, ulcer, acute respiratory distress syndrome, ischemia-reperfusion injury, neurodegenerative disorders, autism, Parkinson's Disease, Alzheimer's Disease, gastrointestinal disease, tissue injury induced by inflammation, and tissue injury induced by an environmental toxin.